Business
GT Biopharma Reports First Quarter 2026 Financial Results
Phase 1 trial evaluating GTB-3650 TriKE® remains ongoing, with additional updates anticipated in 2H 2026 Phase 1 basket trial evaluating GTB-5550 TriKE® in multiple solid tumor types known to express B7-H3 initiated May 2026 with updates anticipated in 2H 2026 as enrollment progresses through dose escalation cohorts Cash balance as of March 31, 2026 of approximately $9 million anticipated to provide sufficient cash runway through Q4 2026 SAN FRANCISCO, CALIFORNIA, May 15, 2026 (GLOBE NEWSWIRE) -
About this update from Gt Biopharma, Inc.
[{"type":"image","alt":"GT Biopharma, Inc.","displaySize":"","headline":null,"caption":"GT Biopharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":215,"height":99,"url":"https://media.zenfs.com/en/globenewswire.com/2255bf0b7d4c7ce859ad7c63f5fbd6ee"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/UEJa_3IAIn5ppJzNvNNoUw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5Mw--/https://media.zenfs.com/en/globenewswire.com/2255bf0b7d4c7ce859ad7c63f5fbd6ee","width":215,"height":99},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/UEJa_3IAIn5ppJzNvNNoUw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5Mw--/https://media.zenfs.com/en/globenewswire.com/2255bf0b7d4c7ce859ad7c63f5fbd6ee","width":215,"height":99}},"lazy":false},{"type":"text","content":"Phase 1 trial evaluating GTB-3650 TriKE® remains ongoing, with additional updates anticipated in 2H 2026","length":104,"tagName":"p"},{"type":"text","content":"Phase 1 basket trial evaluating GTB-5550 TriKE® in multiple solid tumor types known to express B7-H3 initiated May 2026 with updates anticipated in 2H 2026 as enrollment progresses through dose escalation cohorts","length":212,"tagName":"p"},{"type":"text","content":"Cash balance as of March 31, 2026 of approximately $9 million anticipated to provide sufficient cash runway through Q4 2026","length":123,"tagName":"p"},{"type":"text","content":"SAN FRANCISCO, CALIFORNIA, May 15, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager TriKE® platform, today announced first quarter 2026 financial results for the period ended March 31, 2026.","length":376,"tagName":"p"},{"type":"text","content":""With the initiation of our GTB-5550 Phase 1 trial, we have now advanced three TriKE® candidates into the clinic, a significant milestone that underscores the continued momentum of our pipeline," said Michael Breen, Executive Chairman and Chief Executive Officer. "GTB-3650 has demonstrated an excellent safety profile thus far, and we look forward to continuing enrollment progress. With sufficient cash runway through Q4 2026, we look forward to providing updates on both programs in the second half of 2026."","length":531,"tagName":"p"},{"type":"text","content":"GT...